



Paris, 25th of May 2016, 10.30am

***AB Science intends to hold its annual General Meeting of Shareholders  
on June 28, 2016***

**AB Science SA** (the « Company » or « AB Science »), NYSE Euronext – FR0010557264 - AB), will hold its Annual General Meeting of Shareholders (“AGM”) on June 28, 2016, at 4:00 PM in Palais Brongniart, Salle Labarre Centre de Congrès et d’Evènements, Place de la Bourse, 75002 Paris.

The meeting notice of this Shareholders’ Meeting was published on May 23, 2016, in the French official legal bulletin (“BALO”). It includes the agenda, the proposed resolutions as well as instructions to participate and vote in this Meeting.

All documentation regarding this AGM will be made available to shareholders in accordance with existing regulations and will be available on the Company’s website on June 7, 2016.

The 2015 Annual Financial Report (in French) was released on April 29, 2016 and is available on the website of the Company (<http://www.ab-science.com>).

**Precision regarding the AGM:**

Only shareholders having registered their shares at least two business days prior to the date of the AGM, by midnight Paris time, will be able to attend.

Shareholders holding “au porteur” (bearer) shares will need to obtain an “attestation de participation” (certificate of shareholding) from their brokers. This “attestation de participation” must be attached to the proxy form or to the appropriate voting form if shareholders wish to designate a proxy or vote by post. The “attestation de participation” may replace the admission card for shareholders wishing to attend the AGM in person.

Written questions from shareholders must be received until four business days prior to the AGM (by registered letter, addressed to the registered office).

Shareholders may obtain the legal documentation in preparation of the AGM (as described in article R. 225-83 of the French “Code de Commerce”) by sending a request:

- by regular mail to AB Science, Shareholders Services, 3 Avenue George V, 75008 Paris - FRANCE
- by e-mail to [investors@ab-science.com](mailto:investors@ab-science.com)

**About AB Science**

Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment in cancers, inflammatory diseases, and central nervous system diseases, both in humans and animal health.

AB Science has developed a proprietary portfolio of molecules and the Company’s lead compound, masitinib, has already been registered for veterinary medicine in Europe and in the USA. The company is currently pursuing twelve phase 3 studies in human medicine in first-line and second-line GIST, metastatic melanoma expressing JM mutation of c-Kit, multiple myeloma, metastatic colorectal cancer, metastatic prostate cancer, pancreatic cancer, T-cell lymphoma,

severe asthma uncontrolled by oral corticosteroid, Alzheimer's disease, progressive forms of multiple sclerosis, and amyotrophic lateral sclerosis. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).

Further information is available on AB Science website: <http://www.ab-science.com>

*This document contains prospective information. No guarantee can be given as for the realization of these forecasts, which are subject to those risks described in documents deposited by the Company to the Authority of the financial markets, including trends of the economic conjuncture, the financial markets and the markets on which AB Science is present.*

\* \* \*

AB Science – Financial Communication & Media Relations  
[investors@ab-science.com](mailto:investors@ab-science.com)